Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Pfizer's non-COVID product revenues surged 14% operationally last quarter. The oncology business delivered exceptional ...

Pfizer’s Prevnar 20 is a next-generation follow up to its more limited Prevnar 13 and competes with Merck’s Capvaxive, a newer option that scored FDA approval in June. Although Merck’s ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer hired Marra all the way back in 2002, at which time the new Havas Health exec had spent a few years working at Merck ...

Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist ...

The new recommendation could grow a lucrative market for vaccines that’s long been dominated by Pfizer’s Prevnar franchise ... provide broader protection. Merck, for instance, was cleared ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...

Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

The shots are also suggested for certain adults and children who are immunocompromised. A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by ...

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...